4.6 Article

IFCC interim guidelines on rapid point-of-care antigen testing for SARS-CoV-2 detection in asymptomatic and symptomatic individuals

期刊

CLINICAL CHEMISTRY AND LABORATORY MEDICINE
卷 59, 期 9, 页码 1507-1515

出版社

WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2021-0455

关键词

asymptomatic individuals; laboratory-based immunoassays for SARS-CoV-2 detection; point-of-care immunoassays for SARS-CoV-2 detection; SARS-CoV-2 antigen rapid detection tests; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); symptomatic individuals

向作者/读者索取更多资源

This document summarizes the performance data of currently available SARS-CoV-2 antigen rapid detection tests (Ag-RDTs) and provides interim guidance on assay methodology, clinical indications, target populations, test interpretation, limitations, and pre-analytical considerations. The main aim is to assist laboratory and regulated health professionals in selecting and implementing regulatory approved Ag-RDTs.
With an almost unremittent progression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections all around the world, there is a compelling need to introduce rapid, reliable, and high-throughput testing to allow appropriate clinical management and/or timely isolation of infected individuals. Although nucleic acid amplification testing (NAAT) remains the gold standard for detecting and theoretically quantifying SARS-CoV-2 mRNA in various specimen types, antigen assays may be considered a suitable alternative, under specific circumstances. Rapid antigen tests are meant to detect viral antigen proteins in biological specimens (e.g. nasal, nasopharyngeal, saliva), to indicate current SARS-CoV-2 infection. The available assay methodology includes rapid chromatographic immunoassays, used at the point-of-care, which carries some advantages and drawbacks compared to more conventional, instrumentation-based, laboratory immunoassays. Therefore, this document by the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Taskforce on COVID-19 aims to summarize available data on the performance of currently available SARS-CoV-2 antigen rapid detection tests (Ag-RDTs), providing interim guidance on clinical indications and target populations, assay selection, and evaluation, test interpretation and limitations, as well as on pre-analytical considerations. This document is hence mainly aimed to assist laboratory and regulated health professionals in selecting, validating, and implementing regulatory approved Ag-RDTs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据